Cantor Fitzgerald Reiterates Neutral on Bristol-Myers Squibb, Maintains $54 Price Target

بريستول مايرز سكويب كو

Bristol-Myers Squibb Company

BMY

0.00

Cantor Fitzgerald analyst Carter Gould reiterates Bristol-Myers Squibb (NYSE: BMY) with a Neutral and maintains $54 price target.